How many drugs treat Genitourinary Tract Infections?

Drug Landscape tracks 9 marketed treatments for Genitourinary Tract Infections (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/genitourinary-tract-infections.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Genitourinary Tract Infections — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genitourinary Tract Infections (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Genitourinary Tract Infections, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cephalotin	cefalotin	Eli Lilly	cefalotin	Solute carrier family 22 member 8	1974-01-01
Ancef In Sodium Chloride 0.9% In Plastic Container	CEFAZOLIN	GSK	Cephalosporin Antibacterial		1973-01-01
Ancef In Sodium Chloride 0.9% In Plastic Container	Cefazolin Sodium	GSK	Cephalosporin	Bacterial cell wall peptidoglycan	1973-01-01
Amoxil	amoxicillin	Generic (originally Beecham/GSK)	Aminopenicillin (Beta-lactam antibiotic)	5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C	1972-01-01
Unasyn	AMPICILLIN	Bristol-Myers Squibb	Penicillin-class Antibacterial	Transient receptor potential cation channel subfamily M member 4	1965-01-01
Amoxicilli	Amoxicilli	Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.		5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C
Amoxycillin	Amoxycillin	King George's Medical University		5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C
Cefazoline	Cefazoline	Nantes University Hospital		Bacterial penicillin-binding protein, Penicillin-binding protein 1A
Cephazolin	Cephazolin	HaEmek Medical Center, Israel		Bacterial penicillin-binding protein, Penicillin-binding protein 1A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Genitourinary Tract Infections
GSK · 2 drugs in Genitourinary Tract Infections
Eli Lilly · 1 drug in Genitourinary Tract Infections
Generic (originally Beecham/GSK) · 1 drug in Genitourinary Tract Infections
HaEmek Medical Center, Israel · 1 drug in Genitourinary Tract Infections
King George's Medical University · 1 drug in Genitourinary Tract Infections
Nantes University Hospital · 1 drug in Genitourinary Tract Infections
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · 1 drug in Genitourinary Tract Infections
Bristol-Myers Squibb · 1 drug in Genitourinary Tract Infections

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Genitourinary Tract Infections:

Cite this brief

Drug Landscape (2026). Genitourinary Tract Infections — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/genitourinary-tract-infections. Accessed 2026-06-10.

Genitourinary Tract Infections full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing